Amantadine extended release (Gocovri) reduces dyskinesia and bradykinesia: Evaluation of clinical response with the wearable PKG (Personal Kinetigraph) watch
Objective: To determine the effect of bedtime high-dose amantadine extended release (Gocovri) in 50 consecutive patients experiencing motor fluctuations and dyskinesia. Background: Amantadine extended release…Dopaminergics are alternative for the treatment of Bell`s paralysis in acute period
Objective: To study the possibility of using dopaminergic medicines for the treatment of Bell`s paralysis in acute period. Background: In previous reports we conjectured that…Final Safety Results of EASE LID 2 Study: Long Term Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients
Objective: The primary objective of this study was the safety and tolerability of ADS-5102 in PD patients with dyskinesia. Secondary efficacy outcome measures included MDS-UPDRS,…Impact of Dyskinesia in Parkinson’s Disease (PD) on Activities of Daily Living (ADLs) and Daily Tasks: Results from Pooled Phase 3 ADS-5102 Clinical Trials
Objective: To assess the impact of dyskinesias in PD on ADLs and the effects of ADS-5102 (amantadine) extended release capsules on these impairments. Background: ADS-5102…Final MDS-UPDRS, Part IV Results of the EASE LID 2 Study: Long Term, Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients
Objective: An objective of this study was to evaluate the long-term duration of ADS-5102 effect on dyskinesia as assessed by the Unified Parkinson’s Disease Rating…Assessing the potential cost-effectiveness of ads-5102 (Amantadine HCl) for the treatment of dyskinesia in Parkinson’s disease patients
Objective: This economic evaluation projects the likely cost-effectiveness of ADS-5102 in comparison to the current standard of best supportive care. Background: In August, 2017, the…Interim Results of an Ongoing Open-label Safety Study of ADS-5102 (amantadine hydrochloride) Extended-Release Capsules for Treatment of Levodopa-Induced Dyskinesia (LID) (EASE LID 2 Study)
Objective: Characterize the long-term safety and tolerability of 340 mg of ADS-5102 administered once daily at bedtime, for the treatment of LID in Parkinson’s disease…Parkinson’s syndrome as possible manifestation of lamina quadrigemina tumor or inflammation
Objective: Objective of this report is to discuss the case of Parkinson's syndrome (PS) in 22 y.o. patient on the background of the pathological process…Treatment with the use of the PD-specific scales for patients suffering from subcortical Parkinsonian dementia
Objective: Aim of this study was to identify the degree of cognitive dysfunction in patients with subcortical Parkinsonian dementia, during the neuroprotective therapy. Background: Parkinson's…Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke
Objective: To study the possibility of using levodopa and amantadine for the treatment of motor disorders in ischemic stroke after taking the standard treatment. Background:…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.